Intercell
| Intercell AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | FR0004056851 |
| founding | 1997 |
| Seat | Vienna , Austria |
| management | Thomas Lingelbach, CEO |
| Number of employees | 280 (December 2011) |
| sales | 32,884 million € (2011) |
| Branch | biotechnology |
| Website | www.valneva.com |
The Intercell AG was an Austrian biotechnology company based in Vienna, focused on the development of prophylactic and therapeutic vaccines against infectious diseases was specialized. Intercell cooperated with the pharmaceutical companies Novartis , MSD and Sanofi-Aventis . On May 28, 2013, the company merged with the French Vivalis SA to form a company with the company name Valneva SE based in Lyon .
history
The company was founded in 1997 as an offshoot of the Research Institute for Molecular Pathology on Campus Vienna Biocenter in Vienna .
Until 2004, the company was financed through venture capital , and Intercell has been listed on the Vienna Stock Exchange since February 28, 2005 . In June 2006, a capital increase, bringing the company up to the planned achievement of the 2008 took place breakeven is funded.
In early December 2008, a contract between Intercell USA and the United States Department of Health was amended accordingly to provide Intercell with additional payments for the development of the immunostimulating patch for pandemic flu. In May 2009, the corresponding Phase II study was started in the USA.
In mid-December 2008, Intercell received positive responses from the Australian Drug Evaluation Committee and shortly afterwards from the European Medicines Agency's Committee for Human Medicinal Products on the approval of the vaccine against Japanese encephalitis (trade name: Ixiaro ), which led to another milestone payment from major shareholder and cooperation partner Novartis . The drug has been approved in the USA and Europe since April 2009. At the end of March 2009, Intercell signed an exclusive multi-year agreement with the US Department of Defense to acquire Ixiaro.
On April 5, 2010, the company acquired from Cytos Biotechnology Ltd. a technology platform for the identification of monoclonal antibodies for 15 million euros. The technology is based on the expression cloning of monoclonal antibodies from human B cells and enables the identification of anti-infectious antibodies for the prevention and treatment of infectious diseases.
In May 2013 Intercell merged with the French company Vivalis SA , the new company is now called Valneva SE .
Awards
In December 2008, the World Economic Forum named Intercell as the first Austrian company to be the 2009 Technology Pioneer . Also in December 2008, Intercell received the Scrip Award for Biotechnology Company of the Year in London .
Products
- Ixiaro: against Japanese encephalitis, is the company's only vaccine currently available on the market.
Projects
Intercell's ongoing projects that are at least in phase II are:
- a vaccine candidate against Pseudomonas: Intercell and partner Novartis are preparing to start a phase II / III study in early 2012.
- a therapeutic vaccine against hepatitis C.
- a prophylactic, recombinant subunit vaccine against the bacterium Streptococcus pneumoniae , which consists of three highly conserved proteins, and for which the first positive results of a phase I study were published on February 11, 2010.
- a vaccine against tuberculosis , developed jointly with the Danish Statens Serum Institute (SSI) and Sanofi Pasteur .
- a vaccine patch against pandemic influenza
Intercell uses its own antigen identification program and adjuvant technologies to develop these and other planned vaccines .
Known canceled projects are:
- Staphylococcus aureus vaccine candidate : In June, MSD & Intercell announced the discontinuation of the phase II / III clinical trial of the vaccine candidate for the prevention of Staphylococcus aureus . After a detailed analysis of the data from the phase II / III clinical study, the independent Data Monitoring Committee unanimously recommended that the study be discontinued.
- a vaccine patch for traveler's diarrhea . The results of the phase II study were published in The Lancet in 2008 ; the start of the phase III study planned for summer 2009 was prevented by the influenza pandemic of 2009 (the so-called "swine flu") in Mexico. In December 2010, the company announced that it would no longer pursue the project due to non-compliance with effectiveness studies. The failure cost the company up to EUR 183 million.
Web links
- Market data Valneva SE on the Vienna Stock Exchange
Individual evidence
- ↑ a b Annual Report 2011 ( Memento of the original from May 26, 2012 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. (PDF; 1.4 MB)
- ↑ "IXIARO ® from Intercell receives vaccination recommendation from the" Advisory Committee on Immunization Practices "of the Centers for Disease Control and Prevention". (No longer available online.) Intercell AG, June 25, 2009, archived from the original on November 12, 2010 ; Retrieved May 6, 2010 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
- ↑ Intercell signs supply agreement with the US military for IXIARO ® . (PDF; 202 kB) (No longer available online.) Intercell AG, May 8, 2009, archived from the original on April 15, 2010 ; Retrieved May 6, 2010 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
- ↑ Intercell acquires antibody technology platform, opening up new avenues to fight infectious diseases. (PDF) (No longer available online.) Intercell AG, May 6, 2010, archived from the original on May 11, 2010 ; Retrieved May 6, 2010 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
- ↑ The name Intercell disappears from the course sheet. Der Standard , May 14, 2013, accessed August 8, 2013 .
- ↑ Scrip Award Winners 2008 (Eng.)
- ↑ Sarah A Frech, Herbert L DuPont, and others in Lancet Use of a patch containing heat-labile toxin from Escherichia coli against travelers' diarrhea: a phase II, randomized, double-blind, placebo-controlled field trial ( Memento des Originals vom April 15, 2010 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. PDF full text, doi : 10.1016 / S0140-6736 (08) 60839-9 .
- ↑ Intercell provides information on clinical studies of the patch vaccine against traveler's diarrhea. (No longer available online.) Intercell AG, December 12, 2010, archived from the original on January 16, 2011 ; Retrieved April 11, 2011 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
- ↑ Intercell shares plunge 30 percent in early trading. Die Presse , April 11, 2011, accessed April 11, 2011 .
